Introduction {#s1}
============

A *screening test* (sometimes termed medical surveillance) is a medical test or procedure performed on members (subjects) of a defined[^1^](#fn1){ref-type="fn"} asymptomatic population or population subgroup to assess the likelihood of their members having a particular disease.[^2^](#fn2){ref-type="fn"} With few exceptions, screening tests *do not diagnose the illness*. Rather subjects who test positive typically require further evaluation with subsequent *diagnostic tests* or procedures. Examples of actual or proposed screening tests include the pap smear for cervical cancer ([@R11]; [@R78]), mammography (or tomosynthesis) for breast cancer ([@R39]; [@R102]), PSA (and/or digital rectal exam) for prostate cancer ([@R20]), cholesterol level for heart disease, X-ray (or computed tomography) for lung cancer (discussed below), PKU test for phenylketonuria in newborns, B-natriuretic peptide test for screening patients undergoing echocardiography to determine left ventricular dysfunction ([@R74]), and urinalysis or other screening tests for sexually transmitted diseases or illicit drug use ([@R41]; [@R55]; [@R136]). Screening tests may be based on the measurement of a particular chemical in the blood or urine (a quantitative measurement) or some qualitative assessment by a trained observer (e.g. interpretation of an x-ray or CT scan, or semi-quantitative analysis by a polygraph operator).

A major objective of most screening tests is to reduce morbidity or mortality in the population group being screened for the disease by early detection, when treatment may be more successful.[^3^](#fn3){ref-type="fn"} An alternative objective might be to reduce morbidity or mortality in persons other than the screened population who might be impacted by a communicable and preventable disease (such as screening for HIV in blood donors[^4^](#fn4){ref-type="fn"}) among subjects in the population being tested.

Although some of the key analytical/statistical results applicable to the design and evaluation of screening tests have been around since the late 1700s, when the Reverend Thomas Bayes first developed the theorem that bears his name and numerous tutorials or review articles have been written more recently ([@R4]; [@R6],[@R7],[@R8]; [@R26]; [@R42]; [@R64]; [@R122]; [@R144]), there is still some confusion among practitioners about how to interpret and assess the utility of screening tests ([@R19]; [@R47]; [@R76]; [@R137]), which is why the article might be of interest to readers of *Inhalation Toxicology.*

Definitions {#s2}
===========

In its simplest form, the screening test has only two outcomes: positive (suggesting that the subject has the disease or condition) or negative (suggesting that the subject does not have the disease or condition).[^5^](#fn5){ref-type="fn"} An ideal screening test would have a positive result if and only if the subject actually has the disease and a negative result if and only if the subject did not have the disease. Actual screening tests typically fall short (sometimes far short, see below) of this ideal. Instead, most screening tests exhibit what are termed false positives and false negatives to varying degrees. Logical possibilities are described in the 2 × 2 [Table 1](#T1){ref-type="table"}.

###### 

Logical possibilities for true disease state and screening test outcome.

  Test result   Subject has disease           Subject disease free          Subtotal
  ------------- ----------------------------- ----------------------------- -----------------------------
  Positive      Correct result                False positive                Total positive test results
  Negative      False Negative                Correct result                Total negative test results
  Subtotal      Total subjects with disease   Total subjects disease free   Total subjects

In most cases,[^6^](#fn6){ref-type="fn"} screening tests need to be benchmarked against an agreed "Gold Standard" test ([@R45]). The gold standard test is a diagnostic test that is usually regarded as definitive (e.g. by biopsy or autopsy). The actual gold standard test may be invasive (e.g. biopsy), unpleasant, too late (e.g. autopsy) to be relevant, too expensive or otherwise impractical to be used widely as a screening test.

[Table 2](#T2){ref-type="table"} provides examples of various screening tests and possible Gold Standards.

###### 

Examples of screening and diagnostic tests and possible Gold Standards.

  Disease or condition       Screening tests                                                                               Gold Standard                                                                                                          References
  -------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Urinary tract infection    Urine microscopy                                                                              Urine culture                                                                                                          [@R15]
  Congenital heart disease   Exercise ECG                                                                                  Coronary angiography                                                                                                   [@R15]
                                                                                                                           Echocardiography                                                                                                       [@R82]
  Hypertension               Blood pressure (Korotkoff sounds)                                                             Intra-arterial measurement of pressures                                                                                [@R15]
                                                                                                                                                                                                                                                  [@R101]
  Myocardial infarction      EEG or cardiac enzymes                                                                        Cardiac biopsy (at autopsy)                                                                                            [@R15]
  Breast cancer              Mammography                                                                                   Biopsy result                                                                                                          [@R15]
  Bowel cancer               Fecal immunochemical test (FIT) and the fecal occult blood test (FOBT)                        Colonoscopy ± biopsy                                                                                                   [@R15]
  TB                         Tuberculin Skin Test; Interferon Gamma Release Assays                                         Chest X-ray and a sample of sputum, detection of *Mycobacterium tuberculosis* (MTB) by culture or molecular methods.   [@R21] [@R2]
  Chlamydia                  Tissue culture from single cervical swabs                                                     Direct immunofluorescence, enzyme immunoassay, PCR and serology, others                                                [@R121], see [@R136] for review article
  Cervical cancer            Pap smear                                                                                     Colposcopy with appropriate biopsy or sentinel lymph node biopsy                                                       [@R44]
  Celiac disease             IgG- and IgA-antigliadin antibodies, IgA-endomysial antibodies, and intestinal permeability   Small bowel biopsy                                                                                                     [@R134]

In principle, a "Gold Standard" should have 100% sensitivity and 100% specificity (see below for definitions), that is, it would never make a classification error. In practice that may not be the case and the "Gold Standard" is regarded as the best test under "reasonable conditions." As noted by [@R133]:

"As science increases its hold on the practice of medicine we become more aware of the limitations of the clinical method. Unfortunately, we also become more aware of the limitations of various diagnostic tests. Nevertheless, at any given time there may well be a consensus that a given test in a given situation is the best available test. It therefore serves as the gold standard against which newer tests can be compared. When enough data have accumulated to make that gold standard untenable, it can perfectly reasonably be replaced by another. This can then preside until it too is toppled."

[@R125] offered the following perspective on gold standards:

"... however, gold standards for comparison are not always available. Moreover, a perfect gold standard is less often available than an imperfect gold standard ('alloyed gold standard'), an adopted standard based on observed data which is measured with error."

For the purposes of this discussion, the gold standard test is assumed to be without error. Several authors have developed statistical approaches for dealing with "alloyed gold standards" ([@R28]; [@R49]; [@R56]; [@R57]; [@R69]; [@R105]; [@R131]; [@R135]). As might be expected, none of these alternative procedures perform as well as if a true Gold Standard were available, but several are improvements over naively assuming the Gold Standard is "unalloyed."

The possible outcomes shown in [Table 1](#T1){ref-type="table"} are quantified by two probabilities, termed the test *sensitivity* and *specificity.* These are two key characteristics of a screening test. *Sensitivity* is the test\'s ability to correctly designate a subject with the disease as positive; it is the conditional probability (Pr{T^+^\|D^+^})[^7^](#fn7){ref-type="fn"}, denoted by the symbol S that a subject who has the disease, D^+^, tests positive, T^+^. A highly sensitive test means that there are few *false negative* results; few actual cases are missed. *Ceteris paribus*, tests with high sensitivity have potential value for screening, because they rarely miss subjects with the disease ([@R42]).*Specificity* is the test\'s ability to correctly designate a subject without the disease as negative; it is the conditional probability (Pr{T^−^\|D^−^}), denoted by the symbol Sp that a subject who does not have the disease, D^−^, tests negative, T^−^. A highly specific test means that there are few *false positive* results. Therefore, high specificity tests perform well for diagnosis because of low false positive errors. Tests with low specificity have the disadvantage that (among other things) many subjects without the disease will screen positive and potentially receive unnecessary (and possibly invasive, risky or expensive) follow-up diagnostic or therapeutic procedures.

Publications about screening tests typically report both the sensitivity and specificity of the test. It is clearly desirable to have a test that is both highly sensitive and highly specific. (In some cases, it may be possible to structure the test so as to tradeoff sensitivity and specificity, as discussed below.)

[Figure 1](#F1){ref-type="fig"} shows a sample of reported sensitivities and specificities of various screening tests as summarized by [@R4], denoted by the triangles, and from our own literature search (refer [Table A1](#T7){ref-type="table"}), denoted by the circles. As can be seen, there are a substantial number of screening tests with both high sensitivity and high specificity, but also many that fall far short of this ideal. It should be noted that not all the screening tests shown in [Figure 1](#F1){ref-type="fig"} are actually used at present -- some may have been found wanting.

![Reported sensitivity and specificity of a sample of screening tests reported in the literature. Circles are studies summarized here ([Table A1](#T7){ref-type="table"}) while triangles represent studies reported in [@R4].](uiht26_811_f1){#F1}

As some test results (e.g. reading an X-ray) require interpretation, it is possible that there will be inter-observer variation (notwithstanding attempts at standardization) so that the reported sensitivity and specificity may vary with the observer ([@R27]; [@R35] for illustrations). This creates issues when large scale screening tests are being contemplated and it is necessary to extrapolate or generalize from screening test data based on pilot studies, often conducted by highly specialized and experienced personnel. Refer [@R139] and [Table 3](#T3){ref-type="table"} for a useful systematic review of sources of variation and bias in studies of diagnostic or screening accuracy.

###### 

Common sources of bias in study design.

  Type of bias               Description
  -------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  Verification bias          Non-random selection for definitive assessment for disease with the old standard reference test
  Errors in the reference    True disease status is subject to misclassification because the gold standard is imperfect
  Spectrum bias              Types of cases and controls included are not representative of the population
  Test interpretation bias   Information is available that can distort the diagnostic test
  Unsatisfactory tests       Tests that are uninterpretable or incomplete do not yield a test result
  Extrapolation bias         The conditions or characteristics of populations in the study are different from those in which the test will be applied
  Lead time bias             Earlier detection by screening may erroneously appear to indicate beneficial effects on the outcome of a progressive disease
  Length bias                Slowly progressing disease is over-represented in screened subjects relative to all cases of disease that arise in the population
  Overdiagnosis bias         Subclinical disease may regress and never become a clinical problem in the absence of screening, but is detected by screening

Source: [@R96].

Frequently, it is of interest to compare one screening test (a potential improvement) with another. It is important to make careful statistical comparisons to assess whether the "improved" test is actually superior and to calculate confidence intervals on the various proportions (e.g. using the methods given in [@R86]). Ideally such comparisons should be made on the same population and randomly assigning subjects to each test.

Before addressing additional important definitions applicable to screening tests it is appropriate to mention some of the consequences of false negatives and false positives in screening tests. Briefly: A false negative means that a subject with the disease is misclassified as not having the disease on the basis of the screening test. The subject is given a misleading impression that he/she is free of the disease and thus does not undergo more suitable diagnostic tests. At a minimum this means that correct diagnosis is delayed (perhaps until the subject develops symptoms) and, in the case of diseases for which early treatment offers improved chances of recovery, there is increased risk of morbidity and mortality \[refer [@R59] for an example with breast cancer\]. False negatives from a screening test for illicit drug use or a polygraph test design to detect deception have obvious negative consequences ([@R41]). As another example, failure to detect someone with an STD, may result in increased morbidity or mortality of future sexual partners of the subject. Systematic reviews of the consequences of false negatives are provided in [@R98], [@R99]). False negatives may also lead to legal action being taken by affected individuals and may reduce public confidence in screening.A false positive means that a subject without the disease is misclassified as having the disease on the basis of the screening test. The subject is given the misleading impression that he/she has the disease and thus endures the unnecessary psychological consequences as well has having to undergo possibly invasive diagnostic or treatment procedures. The consequences of a false positive can be material. For example: [@R34] provides examples of the consequences of false-positive screening mammograms. Among other things, false-positive mammograms led to more outpatient visits, diagnostic imaging examinations, and biopsies than false positive clinical breast examinations. In one patient, cellulitis requiring hospitalization for surgical debridement and intravenous antibiotic therapy developed after a biopsy prompted by a false positive mammogram.[@R141] provide an assessment of the population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule discovered using a CT scan.[@R24] reported on the cumulative incidence of false-positive results in repeated multimodal cancer screening. Among other things this study revealed that for a woman the cumulative risk of undergoing a false-positive-prompted invasive diagnostic procedure was about 12.3% after 4 tests increasing to 22.1% after 14 tests. For men the corresponding percentages were 17.2% after 4 tests and 28.5% after 14 tests.A study of 12 669 Swedish youths (aged 16 and over) diagnosed with cancer found a 60% increased risk of suicide or attempted suicide ([@R71]). A false positive in this instance has a material adverse consequence.Another study ([@R12]) of people diagnosed with cancer in Queensland, Australia indicated that this group experienced a SMR of 149.9 for non-cancer deaths.False positives may also decrease the likelihood that a subject will return for subsequent follow-up procedures ([@R3]). And, false positives may also result in litigation and loss of public confidence in screening.The consequences of both false positives and false negatives need to be carefully considered in assessing the utility of a screening test. In some cases, it may be possible to alter the decision criterion (or criteria) of a particular screening test to alter the sensitivity or specificity of the test and thus trade off one type of error for another. For such cases, the usual procedure is to calculate a receiver-operating characteristic curve (discussed below) for the test ([@R122]; [@R144]). As well, some of the consequences of false positives can be altered by the choice of follow-up procedures among those subjects who test positive. For example, less invasive or non-invasive diagnostic tests can be selected, depending upon the specific outcomes of the initial screening test.

The *prevalence* of the disease is the fraction, Π, of subjects in the population under study that have the disease. It is equal to the *a priori* probability (Pr{D^+^}) that a subject selected at random from the population or subgroup has the disease.[^8^](#fn8){ref-type="fn"} Prevalence, along with sensitivity and specificity, is a key determinant of the utility of the screening test (see below). For reasons discussed below, it is desirable to be able to define the population to be screened in such a way that the prevalence in the test population is high. The reported prevalence among various populations that are the subject of screening tests ([@R4]) range from 0.05 to 0.9, but clustered among the higher values.

There are four additional relevant characteristics of a screening test, the positive predictive value, negative predictive value, accuracy and likelihood ratio: The *positive predicted value* (PPV) is the probability that a subject with a positive (abnormal) test actually has the disease (Pr{D^+^\|T^+^}) also called the *a posteriori* probability. Given the above notation; PPV = ΠS/((ΠS + (1 -- Π)(1 -- Sp)).

In words, the *a posteriori* probability that the subject has the disease given a positive test is the ratio of true positives (the product of the prevalence and sensitivity) divided by total positives (the sum of true positives and false positives). It is desirable that the screening test has a high PPV. The *negative predicted value* (NPV) is the post-test probability that the subject has no disease given a negative test result (Pr{D^−^\|T^−^}) also termed the *a posteriori* probability given a negative test. Given the above notation: NPV = (1 − Π)Sp/((1 − Π)Sp + Π(1 − S)).

In words, the *a posteriori* probability that the subject does not have the disease given a negative test is the ratio of the true negatives (complement of prevalence times the specificity) divided by the total negatives (the sum of true negatives and false negatives). It is also desirable that the test has a high NPV. The *accuracy* (also termed overall accuracy, diagnostic accuracy or test efficiency) of a test is the overall proportion of correct test results. This includes true positives and true negatives. Mathematically it is calculated from the equation: ΠS + (1 − Π)Sp.

The term ΠS includes the true positives (prevalence times sensitivity) and the term (1 − Π)Sp are the true negatives (probability the subject does not have the disease times the probability that the test is negative given the subject is without disease). As noted by [@R4]: "Overall accuracy is the weighted average of a test\'s sensitivity and specificity, where sensitivity is weighted by prevalence and specificity is weighted by the complement of prevalence." Refer to [@R4] for a discussion of the limitations of this measure of screening efficiency. The *Likelihood ratio* is another term used to characterize screening tests; it is defined as the probability of a subject who has the disease testing positive divided by the probability of a subject who does not have the disease testing positive, L = S/(1 − Sp).

To many, the PPV or NPV are the key characteristics of a screening program. *It is important to remember that the PPV or NPV are dependent on both the population under study and the technical characteristics of the screening test.[^9^](#fn9){ref-type="fn"}* A screening test with relatively high sensitivity and specificity may still have a low PPV if the population prevalence is sufficiently low. Thus, to assess a proposed screening test it is necessary to evaluate both the technical and population characteristics.

The probability of a positive test, Pr(T^+^) is the sum of the probabilities of a subject with the disease correctly testing positive and someone without the disease incorrectly testing positive, or ΠS + (1 − Π)(1 − Sp). Some have suggested using the observed fraction of positive tests, F^+^, (sometimes termed the *apparent prevalence*) as a surrogate for or estimate of Π, but, unless both the sensitivity and specificity are both equal to unity, this will give a biased answer. Given the definitions, an improved estimate for Π is equal to (F^+^ + Sp −1)/(S + Sp − 1). Refer [@R40], [@R41], [@R68] and [@R103] for a derivation and [@R58] for additional analyses.

A numerical example {#s3}
===================

All of these screening test characteristics are determined by testing a particular population (using one or more screening tests) and recording the number of subjects that fall into the various categories shown in [Table 1](#T1){ref-type="table"}. To illustrate, [Table 4](#T4){ref-type="table"} provides a hypothetical data from a screening test evaluation of a population of 10 000 subjects, assumed to have a disease prevalence of 0.5, with a calculated sensitivity of 0.9 (95% confidence interval including continuity correction \[0.8913, 0.9081\]), and a specificity of 0.3 (95% confidence interval including continuity correction \[0.2874, 0.313\]).[^10^](#fn10){ref-type="fn"}

###### 

Hypothetical data from screening experiment.

  Raw Data                                 In symbols                                                                                                                                                                                                                Numerical illustration                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------- --------------------------------- ------------------------------------- --
  Positive                                 a                                                             b                                                                                                                                                           a + b                                    Positive                              4500                                                                               3500                                                          8000                                                                                                                          
  Negative                                 c                                                             d                                                                                                                                                           c + d                                    Negative                              500                                                                                1500                                                          2000                                                                                                                          
  Sub totals                               a + c                                                         b + d                                                                                                                                                       N                                        Subtotal                              5000                                                                               5000                                                          10 000                                                                                                                        
  Definitions                              Term                                                          Definition                                                                                                                                                  Formula                                  Numerical Result                      Alternative Formula or Term                                                                                                                                                                                                                                                    
                                           Prevalence, Π                                                 Fraction of test subjects with disease                                                                                                                      (a + c)/N                                0.5000                                Assumed *a priori* probability of disease,  relatively high in this illustration                                                                                                                                                                                               
                                           Sensitivity, S                                                Fraction of subjects with positive test given that test subject  has disease; "true positive/disease"                                                       a/(a + c)                                0.9000                                Hypothetical data show relatively  high sensitivity                                                                                                                                                                                                                            
                                           False negative rate                                           Fraction of subjects with disease, but with negative test result                                                                                            c/(a + c)                                0.1000                                (1 − S)                                                                                                                                                                                                                                                                        
                                           Specificity, Sp                                               Fraction of test subjects with negative test given that the  test subject does not have disease                                                             d/(b + d)                                0.3000                                Hypothetical data show relatively low specificity                                                                                                                                                                                                                              
                                           False positive rate                                           Fraction of test subjects with no disease, but positive test result                                                                                         b/(b + d)                                0.7000                                (1 − Sp)                                                                                                                                                                                                                                                                       
                                           Probability of positive test                                  True positives + false positives divided by total tests                                                                                                     (a + b)/N                                0.8000                                P(T^+^) = ΠS + (1 − Π)(1 − Sp)                                                                                                                                                                                                                                                 
                                           Probability of negative test                                  True negatives + false negatives divided by total tests                                                                                                     (c + d)/N                                0.2000                                P(T^−^) = Π(1 − S) + (1 − Π)Sp                                                                                                                                                                                                                                                 
                                           Positive predictive value PPV                                 Post-test probability of disease given a positive result                                                                                                    a/(a + b)                                0.5625                                *A posteriori* probability of disease given  positive test result                                                                                                                                                                                                              
                                           Negative predictive value NPV                                 Post-test probability of no disease given a negative test result                                                                                            d/(c + d)                                0.750                                 *A posteriori* probability no disease given  negative test result                                                                                                                                                                                                              
                                           Accuracy                                                      Proportion of correct test results                                                                                                                          (a + d)/N                                0.6000                                ΠS + (1 − Π)Sp                                                                                                                                                                                                                                                                 
                                           Likelihood ratio                                              The probability of a subject who has the disease testing positive  divided by the probability of a subject who does not have the disease testing positive   S/(1 − Sp)                               1.2857                                                                                                                                                                                                                                                                                                               
                                           Regret given positive test                                    Probability that disease free subject has positive test                                                                                                     b/(a + b)                                0.4375                                (1 − Π)(1 − Sp)/(ΠS + (1 − Π)(1 − Sp))                                                                                                                                                                                                                                         
  Bayes Theorem                            Positive test                                                 Negative test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  True state                               P(Hi) *A priori* Probability Person tested is in this state   P(T+/Hi) Probability of positive test in this state                                                                                                         P(Hi)P(T+/Hi) Joint probability          P(Hi/T+) *A posteriori* probability   True state                                                                         P(Hi) *A priori* Probability Person tested is in this state   P(/T−Hi) Probability of negative test in this state   P(Hi)P(T−/Hi) Joint probability   P(Hi/T−) *A posteriori* probability   
  Disease                                  0.5000                                                        0.90                                                                                                                                                        0.4500                                   0.5625                                Disease                                                                            0.5000                                                        0.10                                                  0.0500                            0.2500                                
  No disease                               0.5000                                                        0.70                                                                                                                                                        0.3500                                   0.4375                                No disease                                                                         0.5000                                                        0.30                                                  0.1500                            0.7500                                
  Probability of positive test = P(T^+^)   0.8000                                                                                                                                                                                                                    Probability of negative test = P(T^−^)   0.2000                                                                                                                                                                                                                                                                                                               

Additional references providing useful background: [@R4], [@R33], [@R42], [@R64].

[Table 4](#T4){ref-type="table"} also illustrates the equations and numerical computation of the various quantities defined above. The bottom of [Table 4](#T4){ref-type="table"} provides the calculation (using Bayes\' theorem) of the *a posteriori* probabilities corresponding to either a positive or negative test outcome. In this example, a subject who tests positive has an *a posteriori* probability of having the disease of 0.5625 -- not materially greater than the *a priori* prevalence (0.5) in the population. This is because although the sensitivity is relatively high, the specificity of the test is relatively low. Conversely, a subject who tests negative has an *a posteriori* probability of not having the disease of 0.75 -- in this case, clearly different from the *a priori* prevalence (0.5) in the population in this example.

Further analysis of the numerical example {#s4}
=========================================

The *a posteriori* probability of having the disease given a positive test result, or PPV, is one obvious measure of the evidence provided by the test. Other things being equal, tests with high specificity (few false positives) tend to have a high PPV. However, unlike sensitivity or specificity (which might be termed "pure characteristics" of the test), the PPV is also a function of the characteristics of the population under study; PPV is a function of the prevalence. In the numerical example given in [Table 4](#T4){ref-type="table"}, the prevalence was assumed to be 0.5 (i.e. 50% of the population or subpopulation had the disease). [Figure 2](#F2){ref-type="fig"} shows how the PPV, NPV and accuracy depend upon the assumed prevalence Π in the population being screened. As can be seen, both PPV and accuracy decrease (sharply in the case of PPV) as Π decreases from the base case assumption of 0.50. Conversely, the NPV increases as the prevalence decreases.

![Positive predictive value (PPV), negative predictive value (NPV) and accuracy as a function of assumed prevalence for first numerical example.](uiht26_811_f2){#F2}

To help place the content of [Figure 2](#F2){ref-type="fig"} in perspective, note that if the prevalence, Π, were as low as 0.16, the Positive Predicted Value, PPV, would be only 0.2. Put another way, a subject who tested positive under these circumstances would have an 80% chance of not having the disease! And, if Π were as low as 0.08, *there would be a 90% chance that a subject with a positive test would be disease free.* If the consequences of a positive test (e.g. worry, invasive or expensive and unnecessary follow-up procedures) were substantial, this would not be a satisfactory screening test. Thus, the quantity 1 -- PPV might aptly be termed the *regret probability.*

[Figure 3](#F3){ref-type="fig"} shows how the regret (so defined) varies with both the prevalence and specificity, when the sensitivity is held constant at 0.90. Looking at [Figure 3](#F3){ref-type="fig"}, you can see how the likelihood that a subject who tests positive actually is disease free changes as the prevalence changes. If the actual prevalence in the population were say 0.3, the regret would be approximately 0.7 and if the prevalence were as low as 0.08, the regret would be 0.9. This example illustrates the point that both technical parameters of the screening test and prevalence need to be considered.

![Regret (1 -- PPV) as a function of prevalence ∏ and specificity for example in [Table 4](#T4){ref-type="table"} assuming sensitivity held constant at 0.90.](uiht26_811_f3){#F3}

[Figure 4](#F4){ref-type="fig"} shows the locus of points that have a constant regret (equal to 0.8) as a function of specificity and prevalence for values of sensitivity ranging from 0.7 through 0.9; this test characteristic does not have much leverage in this example. Rather the prevalence and specificity are the key variables.

![Combination of values of prevalence, specificity and sensitivity associated with a regret probability of 0.80.](uiht26_811_f4){#F4}

Although the example given in [Table 4](#T4){ref-type="table"} is hypothetical, it is relevant to many actual tests. One is described below.

An example: LDCT scans for lung cancer {#s5}
======================================

Low dose computed tomography (LDCT) has been proposed as a screening test for lung cancer. Several studies ([@R54]; [@R123]) have shown that this technique has a high sensitivity (as a percentage ranging from 80 to nearly 100%, [@R54]) at detecting nodules. [@R83] published a study reporting that the estimated reduction in mortality from use of LDCT screening was approximately 20% compared to alternative test strategies. Subjects included in the study population were between 55 and 74 years of age at the time of randomization, had a history of cigarette smoking of at least 30 pack-years, and, if former smokers, had quit within the previous 15 years. These criteria were used in an attempt to define a population with a relatively high prevalence and thus a high Positive Predictive Value: Smokers (and those who quit quite recently) are included in the population under test because although lung cancer has multiple risk factors, it is estimated that 85--90% of all cases are attributed to smoking ([@R104]; [@R109]).The age range of the cohort is relevant because older smokers presumably have experienced a greater dose of carcinogens and, as noted by the American Cancer Society:[^11^](#fn11){ref-type="fn"}

  "Lung cancer mainly occurs in older people. About 2 out of 3 people diagnosed with lung cancer are 65 or older; fewer than 2% of all cases are found in people younger than 45. The average age at the time of diagnosis is about 70."

Based on this (and other) research team\'s findings, a nationwide screening program was proposed and has been endorsed by several organizations \[e.g. the American Lung Association, see [@R10], the [@R127]; American College of Chest Physicians (ACCP) and the American Society of Clinical Oncology (ASCO)\].

However, this and earlier proposals for LDCT screening have also had numerous critics or skeptics ([@R9]; [@R50]; [@R104]; [@R113]; [@R132]), some arguing that the estimated benefits of LDCT screening in reducing mortality are uncertain, lower than estimated or absent ([@R13], [@R14]; [@R16]; [@R90]; [@R92]; [@R107]), others that the procedure is not cost-effective ([@R73]), and yet others that the radiation risks might be excessive ([@R18]).

One of the major concerns about the use of LDCT even among advocates ([@R77]) is that LDCT detects a large number of benign but uncalcified pulmonary nodules -- properly termed false positives -- that are challenging to diagnose ([@R72]; [@R84]; [@R94]; [@R119], [@R117], [@R118]) and which create other problems depending upon what is done as part of the follow-up to a positive test ([@R141]). As noted by [@R30]: "Many pulmonary nodules even in smokers are due to benign lesions such as granulomas and hamartomas.[^12^](#fn12){ref-type="fn"}"

In short, although this test is highly sensitive, it has a low specificity. [Table 5](#T5){ref-type="table"} provides estimates of the false positive rate (benign nodules discovered by CT scans) as reported in several studies -- even those that favor routine screening of this population subgroup. The calculated or reported false positive rates shown in [Table 5](#T5){ref-type="table"} vary substantially among the studies;[^13^](#fn13){ref-type="fn"} some of the differences can be explained by different criteria for defining a positive (e.g. size of the nodule that is classified as a positive) and whether or not multiple LDCTs were used (and the criteria for a positive on multiple tests) as part of the procedure. Despite this variability it is apparent that most reported estimates of false positive probabilities are quite high. The study by [@R129] reports a false positive probability very much lower than the other results depicted in [Table 5](#T5){ref-type="table"}. The actual test and decision criteria developed by these investigators differed from others. Specifically, they used a mathematical model to evaluate a non-calcified nodule according to its volume or volume-doubling time. Growth was defined as an increase in volume of at least 25% between two scans. The first-round screening test used by these investigators was considered to be negative if the volume of a nodule was less than 50 mm^3^, if it was 50 to 500 mm^3^ but had not grown by the time of the 3-month follow-up CT, or if, in the case of those that had grown, the volume-doubling time was 400 days or more. Another concern of critics of the NLST is that it might be difficult to generalize the results to community practices. [@R113], for example, wrote: "Participants in the NLST were enrolled in tertiary care hospitals with expertise in all aspects of cancer care. \[LDCT\] studies were interpreted by dedicated chest radiologists with expertise in characterizing nodules and providing appropriate recommendations for follow up. As a result, few patients required invasive testing and radiographic follow-up was sufficient for many patients.However, community radiologists without expertise in evaluating lung nodules may feel compelled to advise invasive testing for a screening-detected nodule. Of the 26 309 persons randomly assigned to chest CT screening in the NLST, 7191 (27%) had an abnormal finding. Most scans (96.4%) yielded false-positive results that were followed by serial radiography. Variation in how nodules are managed could lead to a substantial increase in transthoracic needle aspiration of lung nodules, unnecessary surgery, additional morbidity and even mortality for some persons who never had cancer to begin with."

###### 

Reported false positive rates for CT scans for lung cancer.

  Reported false positives as %   Remarks                                                                                                                                                                           Source
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  96.4                            National Lung Screening Trial Research Team, p. 399                                                                                                                               [@R83]
  96.1                            Study also reports 90% sensitivity                                                                                                                                                [@R117]
  95.5                            106 false positives among 111 with nodules \>0.5 cm                                                                                                                               [@R123]
  92.9--96.0                      Rates depended on nodule size, p. 260.                                                                                                                                            [@R118]
  86.6--96.4                      Rates depend upon assumed nodule size from 5.0 to 9.0 mm                                                                                                                          [@R52]
  94.6                            Based on 14 detected cancers among 259 patients with abnormal CT scans                                                                                                            [@R80]
  94.1                            From [Table 2](#T2){ref-type="table"}, 1773 false positives among 1883 nodules detected                                                                                           [@R73]
  93                              Based on 8 lung cancers among 114 subjects with nodules \>5 mm                                                                                                                    [@R89]
  92.6                            Based on 22 lung cancers among 298 patients with nodules                                                                                                                          [@R91]
  92.1                            Based on 22 cancers in 279 with suspicious nodules                                                                                                                                [@R114]
  88.5--97                        From [Table 3](#T3){ref-type="table"}, rate dependent upon risk                                                                                                                   [@R62]
  87.6                            Based on 29 malignancies among 233 positive results                                                                                                                               [@R51]
  75                              Percent of patients with non-calcified nodules on CT                                                                                                                              [@R75]
  73.4                            Based on 163 benign nodules among 222 evaluated by thin section CT                                                                                                                [@R70]
  \>70                            Reported value derived from Mayo clinic and ELCAP trials                                                                                                                          [@R94]
  62.1                            Based on 18 false positives among 29 subjects; for nodules \>10 mm                                                                                                                [@R29]
  43.75                           Based on 36 confirmed lung cancer cases among 64 patients                                                                                                                         [@R84]
  21--33                          Rates depend upon number of tests, p. 509. Of participants with a false-positive CT scan, 7% had an unnecessary invasive procedure and 2% had major surgery for benign disease.   [@R23]
  19                              p\. 119                                                                                                                                                                           [@R43]
  7.9                             p\. 612. Includes multi-stage process with classification of nodules by size and calcification with follow-up.                                                                    [@R95], [@R107]
  7.9 M/5.6 F                     Sensitivity reported to range between 84.6% W to 90.6% M                                                                                                                          [@R124]
  1.7                             Sensitivity reported at 94.6%, based on Volume CT scanning                                                                                                                        [@R129]

From the data given in [Table 5](#T5){ref-type="table"}, it is clear that a conservative estimate of the false positive probability is at least 0.7, which means that the specificity of this test is at most 0.3 -- the value assumed in the hypothetical example given in [Table 4](#T4){ref-type="table"} -- and might be much lower. Thus, even for the potentially high risk group of elderly heavy cigarette smokers included in the screening trials, the Positive Predictive Value of the test is not likely to be high.

There is some discrepancy in reported PPVs for the NLST; according to [@R54] reported calculated positive predictive values (PPVs) for abnormal screening results ranging from 2.2% to 36.0%, while [@R104] report the PPV for the NLCT as only 3.6%. [@R104] have summarized the PPVs for 14 other LDCT investigations. Including their estimate for the NLCT, PPVs in these tests range from 0.028 to 0.115 with a median value of 0.053 and an arithmetic mean of 0.064, meaning that the probability that someone with a single positive test does not have lung cancer ranges from 0.885 to 0.972!

[@R62] examined how the reduction in lung cancer mortality as reported by the NLST varied with the estimated risk based on a prediction model using age, body-mass index, family history of lung cancer, pack-years of smoking, years since smoking cessation and emphysema diagnosis. Based on model predictions, they divided the study population into quintiles based on a predicted 5-year risk of lung cancer. They analyzed the NLST data and found: "Screening with low-dose CT prevented the greatest number of deaths from lung cancer among participants who were at highest risk and prevented very few deaths among those at lowest risk. These findings provide empirical support for risk-based targeting of smokers for such screening."

This finding highlights the importance of identifying the target population that is likely to benefit most from the screening procedure.

Overdiagnosis is another factor to consider in assessing the merits of LDCT cancer screening. This is because although screening has a high sensitivity and potential to detect aggressive tumors, screening will also detect indolent tumors that otherwise might not cause immediate clinical symptoms. [@R93] used data from the NLST to estimate that more than 18% of all lung cancers detected by LDCT seemed to be more indolent, and the potential of overdiagnosis should be considered when describing the risks of LDCT for lung cancer.

Depending upon what is done in terms of follow up in the event of a positive screening test result, the impact of false positives could be substantial. [@R141] determined population-based estimates of risks of complications following transthoracic needle biopsy of a pulmonary nodule. This group collected data on the percentage of biopsies complicated by hemorrhage, any pneumothorax and pneumothorax requiring chest tube, and computed adjusted odds ratios for these complications associated with various biopsy characteristics, calculated using multivariable population-averaged generalized estimating equations among a population of 15 865 adults (in California, Florida, Michigan and New York) who underwent transthoracic needle biopsy of a pulmonary nodule.

These investigators reported: "Although hemorrhage was rare, complicating 1.0% (95% CI 0.9--1.2%) of biopsies, 17.8% (95% CI 11.8--23.8%) of patients with hemorrhage required a blood transfusion. In contrast, the risk of any pneumothorax was 15.0% (95% CI 14.0--16.0%), and 6.6% (95% CI 6.0--7.2%) of all biopsies resulted in a pneumothorax requiring chest tube. Compared to patients without complications, those who experienced hemorrhage or pneumothorax requiring chest tube had longer lengths of stay (*p* \< 0.001) and were more likely to develop respiratory failure requiring mechanical ventilation (*p *= 0.02). Patients aged 60--69 years (as opposed to younger or older patients), smokers and those with chronic obstructive pulmonary disease had higher risk of complications."

It is apparent form these results that the consequences of false positives are potentially material.

Based largely on concerns over the high false positive rate, the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) in the United States recently recommended against covering the procedure for this patient group based on a lack of evidence to support the benefits of the screening test (<http://www.aafp.org/news/health-of-the-public/20140521medcacctrec.html>). MEDCAC makes recommendations, not decisions; as noted by the Centers for Medicare and Medicaid Services (<http://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/MEDCAC.html>): "The MEDCAC reviews and evaluates medical literature, technology assessments, and examines data and information on the effectiveness and appropriateness of medical items and services that are covered under Medicare, or that may be eligible for coverage under Medicare. The MEDCAC judges the strength of the available evidence and makes recommendations to CMS based on that evidence."

The merits of this screening test are likely to be reviewed by other panels and the MEDCAC recommendation may ultimately be reversed -- the Centers for Medicare & Medicaid Services (CMS) is expected to issue a proposed decision on the issue by November 2014, and a final decision in February 2015. The decision may be made on policy grounds but, from a scientific perspective, the ultimate outcome is likely to hinge on the judgment of the key parameters prevalence in the population, the high false positive rate, and ultimately the low PPV ([@R85]; [@R100]; [@R127]).

Another example of LDCT screening {#s6}
=================================

As a related example, we were asked by ECFIA (a trade association of manufacturers of high temperature insulating wools) to comment on the suitability of routine use of LDCT scans in a medical surveillance program for workers of all ages (including both smokers and non-smokers) engaged in the manufacture of refractory ceramic fiber (RCF) and other high temperature insulating wools in France. The available results of a mortality study of these workers in two US plants does not indicate any increase over baseline cancer rates ([@R67]; [@R128]), so the likely prevalence of lung cancer in this population is not likely to be high. This is because most of the employed population is substantially younger than those included in the NLST (indeed, the retirement age in France is 60--62 depending upon what age the employee entered the workforce) and not all employees are smokers, let alone heavy smokers.

According to data from SEER (see <http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer>) the lifetime probability of contracting lung cancer among American males (including both smokers and non-smokers) is approximately 7.6%. Taking this as an estimate applicable to the French population prevalence[^14^](#fn14){ref-type="fn"} and using the sensitivity and specificity values from [Table 4](#T4){ref-type="table"}, the positive Predictive Value of CT lung cancer screening is approximately 0.1. (Obviously it would be much lower for young men and non-smokers and higher among those nearing retirement and heavy smokers.) This means that the *a posteriori* probability (regret) that a subject who tests positive in a single CT scan *does not have lung cancer* is approximately 0.9. Despite the high probability that a subject with a positive test does not have lung cancer, these subjects would be subject to whatever follow-up procedures might accompany such a test result. Members of this group would, at a minimum, suffer some mental distress and would be subject to follow-up CT scans and possibly invasive procedures. This screening test would clearly be inappropriate for this group. In this context it is noteworthy that the American Lung Association\'s guidance document ([@R10]) that endorsed LDCT scans for older smokers also states: "Low-dose CT screening should NOT be recommended for everyone. \[Emphasis in original.\]"

And, [@R14] also endorsed LDCT screens for older smokers, but also recommended:[^15^](#fn15){ref-type="fn"}"For individuals who have accumulated fewer than 30 pack-years of smoking or are either younger than 55 years or older than 74 years, or individuals who quit smoking more than 15 years ago, and for individuals with severe comorbidities that would preclude potentially curative treatment, limit life expectancy or both, we suggest that CT screenings should not be performed."

Thus, regardless of whether one believes that LDCT is an appropriate screening test for the population of older smokers, it is not justified for a population with much lower prevalence or those who are not likely to benefit from a correct diagnosis, evaluation and treatment.

Periodic screenings {#s7}
===================

Some screening tests are designed as "once-off" tests, but many are intended to be administered periodically, such as annually. For example, mammography and clinical breast examination have been proposed for screening for breast cancer. As [@R34] wrote: "If a woman undergoes annual screening beginning at the age of 40, she will have had 60 opportunities for a false positive result by the age of 70, with 30 mammograms and 30 clinical breast examinations. The cumulative lifetime risk from her having a result from a screening test that requires further workup, even though no breast cancer is present, is not known...It is important to determine the cumulative risk of false positive tests, because women are advised to have breast-cancer screening every 1--2 years over several decades of their lifetimes, and false positive rates can provoke anxiety, increase costs and cause morbidity."

Thus, in evaluating periodic screening, it is necessary to measure or calculate cumulative probabilities. Care must be taken because the results of multiple tests may not be independent events.

Choosing the right population subgroup {#s8}
======================================

As the PPV of a screening test depends critically on the prevalence of the disease in the population it is important to identify criteria to define a population group or subgroup with a high disease incidence to begin with. As noted above, this is why the LDCT program was limited to older smokers. Lung cancer rates increase with age and the vast majority of lung cancers occur in smokers. This is potentially a reasonable population subgroup for screening.

To illustrate the selection of a relevant population subgroup, we use an example from a study of breast cancer screening. [@R60] reported on a cross-sectional study of 31 814 women aged 30 years and older referred for mammography at the University of California. They segmented the population into women of various age groups with and without a family history of breast cancer. [Figure 5](#F5){ref-type="fig"} shows a bar chart of the estimated PPVs for these groups. These investigators found that five times as many cancers per 1000 first-screening mammographic examinations were diagnosed in women aged 50 years or older compared with women aged less than 50 years. The highest PPVs for mammography were older women with a family history of breast cancer. This finding guided their recommendation.

![Positive predictive value from mammography for women in various age groups with and without a family history of cancer according to data provided in [@R60].](uiht26_811_f5){#F5}

Possible criteria for defining a population subgroup include various demographic factors (age, gender, race and country), known risk factors (e.g. smoking), medical history and occupation. For screening to be highly effective, the prevalence in the population should be as high as is practicable. [@R48] provides additional comments on the importance of the study population.

ROC curves {#s9}
==========

It is noted above that there may be opportunities to design a screening test that has different combinations of sensitivity and specificity. If so, there are opportunities to design the test to possess characteristics that are superior in terms of the combination of possible consequences of false positives and false negatives. For example in the LDCT test, the threshold for size (mm) of the nodules or other characteristics (e.g. solid or semisolid nodules) might be varied ([@R65]), choices that would alter the sensitivity or specificity. [@R122] and [@R144] offer other relevant examples of ROC curves.

[Figure 6](#F6){ref-type="fig"} shows a typical receiver operating characteristic (ROC)[^16^](#fn16){ref-type="fn"} curve for a prostate specific antigen (PSA) test administered to men aged 70 or more.

![Receiver operating characteristic curve of prostate specific antigen (PSA) test, based on data from [@R122] among men aged 70 or more. Numbers shown are the specific cutoff on the PSA test result. The area under the curve (AUC) in this case is 0.678.](uiht26_811_f6){#F6}

Each subject is tested and a specific PSA score determined. Subjects were also administered digital rectal examinations and biopsies -- those with positive biopsies were used as the gold standard for assessment of disease status. A series of possible PSA cutoff scores (measured in nanograms per milliliter ng/ml) were considered for the screening test. Each cutoff score resulted in a partitioning of subjects into those who tested positive and those who tested negative. Knowing the actual disease status of the subjects enabled calculation of the sensitivity and specificity of the test. The ROC curve plots the calculated sensitivity against the false positive error (1 -- Sp). Thus, each plotted point on the curve represents a different possible screening test with its own sensitivity and specificity. By considering the consequences of false positives and false negatives, it is possible to determine a cutoff value for the PSA test that is optimal in some sense. One statistic often used to characterize the ROC is the area under the curve (AUC). A perfectly discriminatory ROC would have an AUC = 1.0. The value for the PSA tests studied by [@R122] was 0.678.

[@R122] also considered using a so-called Gleason score[^17^](#fn17){ref-type="fn"} with a cutoff of 8 or more in this population. [Figure 7](#F7){ref-type="fig"} shows the ROC curve (topmost curve) for this possible screening test. As can be seen, this series of tests dominates the tests based upon PSA score alone (the AUC in this case is 0.827). The dashed line in [Figure 7](#F7){ref-type="fig"} shows the ROC curve that would occur under chance alone.

![Receiver operating characteristic curves of prostate specific antigen (PSA) test, based on data from [@R122] among men aged 70 or more (AUC = 0.678). The top curve uses a combined PSA and Gleason Grade \> 8 score (AUC = 0.827). The bottom curve is what would be expected by chance alone (AUC = 0.50).](uiht26_811_f7){#F7}

Whether or not and for whom PSA screening is appropriate requires the same sort of analysis noted for the LDCT screening evaluation. The ROC curve is just one piece of the puzzle, but this type of analysis shows that it is possible to design a screening test with several alternative combinations of sensitivity and specificity.

A complete specification of a screening test includes the intrinsic test characteristics (sensitivity, selectivity and cost) and ROC curve (if multiple tests are possible), characteristics of the subject population (including opportunities for segmenting the population to identify high risk groups), the key derived quantities (PPV and NPV) and the consequences of false positives and negatives.

Concluding remarks {#s10}
==================

Screening tests have the potential to be a cost effective means for identifying subjects with early stage (and thus potentially more treatable) disease before symptoms develop and therefore, for saving lives. The ideal screening test would discriminate perfectly between those who have or do not have the disease and be inexpensive and not invasive. In practice, screening tests exhibit false positives and false negatives -- errors with consequences that need to be carefully considered when evaluating the advantages and disadvantages of the test.

The predictive value of the test depends in part on the technical parameters of the test, including the sensitivity and specificity, but also on the prevalence of the disease in the population. For this reason, it is necessary to be able to define the population to be tested so that the prevalence is high. This is why mammography is appropriate only for older women and those with a family history of breast cancer and why lung CT scans are not appropriate for screening the general population.

With some screening tests it is possible to alter the test decision criterion to alter the balance between sensitivity and specificity in which case it may be possible to develop an optimal screening test.

Nonetheless, screening of asymptomatic populations is not always appropriate and could do more harm than good.[^18^](#fn18){ref-type="fn"} [Table 6](#T6){ref-type="table"} summarizes the circumstances/conditions when screening might be either appropriate or contra-indicated.

###### 

Circumstances/conditions when screening might be appropriate or contra-indicated.

  Circumstances favoring screening                                                                                                                                                                                                                  Circumstances when screening not appropriate
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease constitutes a significant public health problem, meaning that it is a relatively common condition with significant morbidity and mortality or disease is contagious and might infect others before symptoms occur and disease detected.   Disease is rare or not serious or, if serious there is no effective treatment for disease.
  The population to be screened can be so defined that the prevalence is high and there are no significant co-morbidities.                                                                                                                          Unknown or low population prevalence
  Treatment before symptoms occur is more effective than if treatment is delayed                                                                                                                                                                    No benefit to early treatment and/or significant likelihood of overdiagnosis (pseudodisease)
  "Gold Standard" diagnostic exists and screening test sensitivity and specificity is high and based on adequate sample size                                                                                                                        Screening test data is based on small sample sizes or is difficult to extrapolate to larger pool of screening centers with high sensitivity and specificity (e.g. high inter-observer variability)
  Consequences of false negative or false positives are modest                                                                                                                                                                                      Consequences of one or more of these errors significant
  Screening test is inexpensive, easy to administer, not harmful and reliable                                                                                                                                                                       Any of these circumstances not met
  There must be some mechanism for follow-up of subjects with positive screening results to ensure subsequent diagnostic testing and ultimate treatment takes place.                                                                                

Sources: [@R47], [@R53], [@R142].

We appreciate the constructive comments offered by two anonymous reviewers. Their comments have improved this manuscript.

^1^The basis for definition of the population might include age, gender, race, occupation, known medical condition or other risk factor (e.g. smoking).

^2^Diseases frequently begin before the onset of symptoms during a period sometimes referred to as the "detectable pre-clinical Phase" (DPCP).

^3^From this, it follows that the benefits of screening will be minimal if the disease has no cure (such as certain stage mesotheliomas) or if early detection does not materially improve chances for survival. In addition, depending upon the population under study, some diseases (sometimes termed pseudo diseases) are detected that do not affect mortality because the subject may die from another disease or event. This is termed *overdiagnosis* (refer [@R16] for more detail).

^4^Screening tests for donated blood using nucleic acid amplification are now so efficient that the risks of human immunodeficiency virus and hepatitis C virus transmission through blood transfusion is estimated to be approximately 1 in 2 million ([@R116]).

^5^See [@R22] for an extension in which the test results are permitted to fall into three zones, a positive, negative and in intermediate "grey zone." In principle, many test outcomes as well as sequential tests can be handled mathematically. We focus on the 2 × 2 because it has proven useful and is easier to analyze.

^6^There are a few examples (e.g. certain tests for HIV) of screening tests with such high sensitivity and specificity that they are virtually a Gold Standard.

^7^The symbols T+ and T− denote the events that the test outcome is positive and negative, respectively. The symbols D+ and D− denote the events that the subject has or does not have the disease.

^8^Thus, Pr{D−} = 1−Π.

^9^It is beyond the scope of this article to consider optimal screening study designs, but it is appropriate to comment on one possible design, the case control design. As noted by [@R42]: "It is important to highlight that the case control study design cannot be used to determine predictive values because these values are influenced by disease prevalence. Because cases and controls are selected for inclusion, the prevalence of the disease is, therefore, "fixed" by the study design. Reproducing a generalizable spectrum of patients also becomes difficult with this type of study design".

^10^The width of these confidence intervals is small due of the assumed size of the population under test. Many studies, however, are conducted on few individuals and it is important to understand the consequences in terms of the likely precision of the estimates.

^11^See <http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics>.

^12^A hamartoma is a benign, focal malformation that resembles a neoplasm in the tissue of its origin.

^13^This is obviously not desirable, but also not entirely unexpected. For example, [@R35] noted a variation in false positive rates ranging from 2.6% to 15.9% among radiologists interpreting mammograms.

^14^Male mortality rates from lung cancer are approximately the same in France and the United States (see <http://www.oecd-ilibrary.org/docserver/download/8111101ec007.pdf?expires=1404337643&id=id&accname=guest&checksum=03F45C46CE1A31E393DD2EAFDF0157D3>). Moreover, the 7.6% figure assumed for the prevalence is for an entire lifetime. The probability of contacting cancer through age 60 or 62 (when workers will retire) is certainly lower. Thus, this estimate probably overstates the actual prevalence for the worker cohort.

^15^ACCP and ASCO have made essentially the same recommendation, see <http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/lung-cancer-screening>.

^16^ROC analysis emerged from the study of signal detection problems differentiating signals from noise. These were first used by scientists in Britain during World War II as the abilities of radar receiver operators were being assessed based on their ability to differentiate signal (e.g. enemy aircraft) from noise (non-relevant targets). The term was later borrowed by statisticians assessing screening tests.

^17^The Gleeson score is a grading system for prostate cancer based on microscopic appearance of the tumor.

^18^For a discussion of ethical issues relevant to screening programs ([@R79]; [@R143]).
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###### 

Table of test specificity and sensitivity results in the literature.

  References   Test Information                                                              Specificity                      Sensitivity            
  ------------ ----------------------------------------------------------------------------- -------------------------------- ------------- -------- --------
  [@R81]       Multi-modal and ultrasound for ovarian cancer;  primary ovarian and tubal     0.998                            0.894                  
               Primary invasive epithelial ovarian and tubal                                 0.998                            0.895                  
               USS                                                                           0.982                            0.75                   
               [@R130]                                                                       0.987                            0.763                  
  [@R46]       Renal vascular hypertension screening test                                    0.92                             0.93                   
  [@R138]      HTLV-III (AIDS Agent) screening test                                          0.986                            0.973                  
  [@R115]      PTSD screening test                                                           0.975                            0.77                   
  [@R63]       HPV testing thin-layer pap                                                    0.824                            0.613                  
               PCR                                                                           0.788                            0.882                  
               Signal amplification                                                          0.726                            0.908                  
  [@R97]       Peripheral neuropathy in Diabetes clinic                                      Vibration (on off)               0.99          0.53     
                                                                                             Monofilament                     0.96          0.77     
                                                                                             Superficial pain                 0.97          0.59     
                                                                                             Vibration (timed)                0.98          0.8      
  [@R26]       Obstructive airway disease and \>40 pack-years smoking                                                         0.986         0.284    
  [@R32]       ABI and stroke                                                                CHD                              [@R87]        0.908    0.163
                                                                                                                              [@R1]         0.944    0.167
                                                                                             Stroke                           [@R87]        0.908    0.17
                                                                                                                              [@R1]         0.887    0.22
                                                                                                                              [@R126]       0.972    0.092
  [@R110]      HPV DNA testing for cervical cancer                                                                            0.942         0.771    
                                                                                                                              0.934         0.748    
  [@R78]       HPV for cervical cancer (conservative case)                                                                    0.941         0.946    
               Pap for cervical cancer (conservative case)                                                                    0.968         0.554    
  [@R106]      Autologous serum skin tests to screen for  chronic idiopathic urticaria                                        0.81          0.65     
                                                                                                                                            0.78     0.71
  [@R74]       B-natriuretic peptide for left ventricular dysfunction,  75 pg/mL BNP level                                    0.98          0.86     
  [@R112]      Probability of falls by timed up and go test                                                                   0.87          0.87     
  [@R37]       Endomysial antibody screening for coeliac disease,  four tests                                                 0.99          1        
                                                                                                                              0.99          0.91     
                                                                                                                              0.85          0.91     
                                                                                                                              0.88          0.76     
  [@R136]      Various tests for Chlamydia                                                   PCR cervix                       1             0.965    
                                                                                             LCR urine                        1             0.875    
                                                                                             EIA urine                        1             0.188    
                                                                                             EIA cervix                       1             0.52     
                                                                                             EIA cervix                       0.99          0.8      
                                                                                             DNA probe                        0.96          0.72     
                                                                                             LET urine                        0.808         0.778    
                                                                                             EIA urine                        0.99          0.75     
                                                                                             EIA cervix                       1             0.844    
                                                                                             PCR cervix                       1             1        
                                                                                             LCR urine                        1             0.96     
                                                                                             EIA urine                        1             0.37     
                                                                                             EIA cervix                       1             0.783    
                                                                                             PCR cervix                       1             1        
                                                                                             PCR cervix                       1             0.85     
                                                                                             PCR cervix                       1             0.953    
                                                                                             PCR cervix                       0.986         1        
                                                                                             PCR urine                        0.986         0.923    
                                                                                             LCR cervix                       0.997         0.886    
                                                                                             PCR, EIA cervix                  0.997         0.97     
                                                                                             LET                              0.91          0.41     
                                                                                             LCR and LET urine                0.949         0.589    
                                                                                             PCR urine                        0.997         0.82     
                                                                                             PCR cervix                       0.998         0.82     
                                                                                             PACE2 cervix                     1             0.795    
                                                                                             PCR urine                        0.99          0.85     
                                                                                             DFA cervix                       0.96          0.85     
                                                                                             LCR urine                        1             0.882    
                                                                                             EIA                              1             0.84     
                                                                                             PCR cervix                       0.998         0.992    
                                                                                             LCR, PCR                         1             0.93     
                                                                                             LCR, PCR                         0.996         0.62     
                                                                                             DFA cervix                       0.995         0.778    
                                                                                             PCR cervix                       1             0.714    
                                                                                             EIA cervix                       1             0.647    
                                                                                             PCR urine                        0.993         0.895    
  [@R11]       Five cervical cancer screening tests ([Table 3](#T3){ref-type="table"})       VIA                              0.836         0.887    
                                                                                             VILI                             0.832         0.957    
                                                                                             VIAM                             0.855         0.826    
                                                                                             Pap Smear                        0.985         0.651    
                                                                                             HC2                              0.93          0.721    
  [@R66]       Fasting glucose to insulin ratio to measure insulin sensitivity                                                0.84          0.95     
  [@R111]      Noninvasive determination of endothelium-mediated vasodilation                Coronary artery disease          0.81          0.71     
                                                                                             Angina pectoris                  0.571         0.824    
  [@R5]        Four tests for colorectal-screening                                           Hemoccult II                     0.981         0.324    
                                                                                             Hemoccult II Sensa               0.875         0.712    
                                                                                             Hemoselect                       0.952         0.672    
                                                                                             Combined                         0.979         0.537    
  [@R36]       Pulse oximetry screening for congenital heart defects                         Critical cases                   0.9912        0.75     
                                                                                             All major cases                  0.9916        0.4906   
  [@R17]       Saliva polymerase chain reaction assay for cytomegalovirus                    Liquid Saliva                    0.999         1        
                                                                                             Dried Saliva                     0.999         0.974    
  [@R140]      Several colorectal cancer screening tests                                                                      0.94          0.85     
                                                                                                                              0.944         0.688    
                                                                                                                              0.91          0.875    
                                                                                                                              0.949         0.865    
                                                                                                                              0.831         0.667    
                                                                                                                              0.969         0.818    
                                                                                                                              0.971         0.556    
                                                                                                                              0.956         0.909    
  [@R25]       Six human papillomavirus tests                                                BD HPV                           0.843         0.975    
                                                                                             Roche Cobas                      0.845         0.975    
                                                                                             Qiagen Hybrid                    0.854         0.975    
                                                                                             Abbott real time                 0.872         0.95     
                                                                                             Gen-probe                        0.902         0.975    
                                                                                             NorChip                          0.952         0.714    
  [@R31]       Various tests for gestational diabetes                                        50-G OGCT                        0.86          0.85     
                                                                                             50-G OGCT                        0.84          0.88     
                                                                                             50-G OGCT                        0.83          0.85     
                                                                                             50-G OGCT                        0.69          0.81     
                                                                                             50-G OGCT                        0.89          0.7      
                                                                                             50-G OGCT                        0.77          0.99     
                                                                                             50-G OGCT                        0.66          0.88     
                                                                                             50-G OGCT                        1             0.17     
                                                                                             Fasting plasma glucose           0.52          0.87     
                                                                                             Fasting plasma glucose           0.76          0.77     
                                                                                             Fasting plasma glucose           0.92          0.76     
                                                                                             Fasting plasma glucose           0.93          0.54     
                                                                                             HbA 1c                           0.28          0.92     
                                                                                             HbA 1c                           0.97          0.12     
                                                                                             HbA 1c                           0.61          0.86     
                                                                                             HbA 1c                           0.21          0.82     
  [@R88]       MRI and mammographic screening in survivors of Hodgkin Lymphoma               Mammogram                        0.93          0.68     
                                                                                             MRI                              0.94          0.67     
                                                                                             Both                             0.9           0.94     
  [@R55]       Various tests for syphilis (imperfect reference)                                                                                      
                                                                                             Determine                        Serum         0.9415   0.9004
                                                                                                                              Whole Blood   0.9585   0.8632
                                                                                             SD Bioline                       Serum         0.9585   0.8706
                                                                                                                              Whole Blood   0.9795   0.845
                                                                                             Syphicheck                       Serum         0.9914   0.7448
                                                                                                                              Whole Blood   0.9958   0.7447
                                                                                             Visitect                         Serum         0.9645   0.8513
                                                                                                                              Whole Blood   0.9943   0.7426
  [@R108]      Various tests for prostate cancer                                             Optimized                        0.9           0.8      
  [@R61]       Various tests for blood-based breast  cancer screening                        RASSF1A UTIH5                    0.73          0.54     
                                                                                             RASSF1A DKK3                     0.75          0.59     
                                                                                             DKK3 ITIH5                       0.94          0.4      
                                                                                             RASSF1A DKK3 ITH5                0.72          0.67     
  [@R38]       Cervical cancer screening methods in HIV positive women CIN 2+                Cytology (MD intern)             0.681         0.755    
                                                                                             HPV                              0.514         0.919    
                                                                                             Cytology (RN intern)             0.685         0.654    
  [@R120]      Breast tomosynthesis compared to mammography for detection of cancer          Mammography                      0.883         0.963    
                                                                                             Tomosynthesis                    0.867         0.963    
  [@R102]      Breast tomosynthesis compared to mammography for detection of cancer          Mammography                      0.841         0.655    
                                                                                             Mammography plus                 0.892         0.762    
                                                                                             Tomosynthesis                    0.862         0.627    
                                                                                             Mammography                      0.845         0.787    
                                                                                             Mammography plus Tomosynthesis                          
  [@R20]       Prostate-specific antigen in serum screening test                             Rectal examination               0.44          0.86     
                                                                                             Ultrasonography                  0.27          0.92     
                                                                                             Serum PSA                        0.59          0.79     
